Fisher & Paykel Healthcare (ASX: FPH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Fisher & Paykel Healthcare Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Fisher & Paykel Healthcare (ASX: FPH)
Latest News
Healthcare Shares
3 ASX 200 healthcare shares to buy while they're on sale
Dividend Investing
15 ASX shares going ex-dividend before EOFY
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Fisher & Paykel Healthcare, GR Engineering, Kogan, and Wesfarmers shares are pushing higher
Earnings Results
Guess which ASX 200 stock is jumping 9% on FY26 results
Share Market News
Are these 4 ASX All Ords stocks a buy after rebounding from 52-week lows?
Share Market News
This ASX 200 healthcare stock has crashed to a multi-year low: Here's why and what's next
Healthcare Shares
What's making healthcare the worst sector on the ASX 200, down 39% in a year?
52-Week Lows
These 4 ASX 200 shares have slumped to fresh 52-week lows: Buy, sell or hold?
Share Market News
Fisher & Paykel Healthcare upgrades FY26 earnings outlook
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.
-
Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.
-
Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.
-
Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.
-
Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.
The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.
Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Sir Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Sir Daniell is a director of Cochlear, Tait International and the Medical Research Commercialization Fund. He was named a Knight Companion of the New Zealand Order of Merit in June 2021. She is the Chair, Quality, Safety and Regulatory Committee and a member of the People Committee.
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon spent 15 years as Senior Vice President - Products & Technology, and six years as General Manager - Research & Development. During his 43-year tenure with Fisher & Paykel Healthcare, he has held various engineering positions overseeing the development of our range of products as well as the development of our manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive DirectorNon-Executive Chairman | Nov 2018 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and a former director of The Board of Tax, Southeastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is a member of the Risk, People and the Member, Quality, Safety and Regulatory Committee.
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Oct 2021 |
Dr McIntyre is a director of Medibank, The University of Sydney, Studiosity and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to health and life sciences companies in North America, Asia and Australia. She is the Chair of the People Committee and a member of the Risk Committee.
|
| Mr Andrew Mark Cross | Non-Executive Director | Oct 2024 |
Mr Cross chairs the boards of Chorus and Vocus and is a director of Xero. He is a former chair of Milford Asset Management and a former director of Accident Compensation Corporation, Z Energy, Genesis Energy and Argosy Property. Mark previously held worked with Deutsche Bank in Sydney and London and Lloyds Corporate Finance/ Southpac Corporation in New Zealand, where he was an advisor to companies across a range of sectors. He is Chair of the Risk Committee.
|
| Mr Graham McLean | Non-Executive Director | Oct 2023 |
Mr McLean is chair of CleanSpace Technology and a director of the Additive Manufacturing Cooperative Research Centre. He previously spent 16 years as an executive at medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is a member of the Risk Committee.
|
| Dr Cather Simpson | Non-Executive Director | Jun 2022 |
Dr Simpson is the CEO of Orbis Diagnostics and a partner at Pacific Channel, with expertise in lasers and photonics. She is President-Elect of the International Society for Optics and Photonics (SPIE) and a member of the Academy Executive Committee of the Royal Society Te Aparangi. Cather is a co-founder of three deep-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She serves on the board of the New Zealand Institute for Advanced Technology, a public research organization. He is a Member, Quality, Safety and Regulatory Committee.
|
| Ms Anna Curzon | Non-Executive Director | Feb 2026 |
Ms Curzon has more than 25 years of experience in the technology and financial services industries. Over her career, she has served as Managing Director NZ, Chief Partner Officer and Chief Product Officer at Xero, and she has held management or advisory roles with several other technology companies. Anna is a director of Gallagher Holdings, Kiwibank and Jade Software Corporation. She chairs the board of Atomic.io as well as the Regional Economic Integration Working Group of the APEC Business Advisory Council. He is a member of the People Committee.
|
| Ms Raelene Leonard | Company Secretary |
-
|
|
| Lyndal York | Chief Financial Officer |
-
|
|
| Andy Niccol | Chief Operating Officer |
-
|
|
| Raelene Leonard | Company Secretary |
-
|
|
| Desh Edirisuriya | General Manager - New Zealand Operations |
-
|
|
| Marcus Driller | Vice President - Corporate |
-
|
|
| Nicola Talbot | Vice President - Human Resources |
-
|
|
| Nicholas Fourie | Vice President - Information & Communication Technology |
-
|
|
| Jonti Rhodes | Vice President - Network Design Facilities Infrastructure & Sustainability |
-
|
|
| Andrew Somervell | Vice President - Products & Technology |
-
|
|
| Brian Schultz | Vice President - Quality Safety & Regulatory Affairs |
-
|
|
| Justin Callahan | Vice President - Sales & Marketing |
-
|
|
| Winston Fong | Vice President - Surgical Technologies |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| JPMorgan Nominees Australia Pty Limited | 71,210,564 | 12.13% |
| HSBC Nominees (New Zealand) Limited R601127393 | 67,120,524 | 11.43% |
| HSBC Custody Nominees (Australia) Limited | 56,513,111 | 9.62% |
| BNP Paribas Nominees NZ Limited R601338998 | 45,770,290 | 7.79% |
| HSBC Nominees (New Zealand) Limited R601127385 | 43,422,137 | 7.39% |
| JPMorgan Chase Bank | 43,034,426 | 7.33% |
| Citibank Nominees (NZ) Ltd | 40,460,585 | 6.89% |
| Citicorp Nominees Pty Limited | 33,335,759 | 5.68% |
| Custodial Services Limited | 19,072,478 | 3.25% |
| Apex Custodian Nominees | 15,154,403 | 2.58% |
| New Zealand Superannuation Fund Nominees Limited | 14,159,552 | 2.41% |
| BNP Paribas Nominees Pty Ltd | 7,435,141 | 1.27% |
| Public Trust | 6,798,911 | 1.16% |
| BNP Paribas Nominees NZ Limited R601339005 | 6,774,688 | 1.15% |
| Accident Compensation Corporation | 6,512,787 | 1.11% |
| New Zealand Permanent Trustees Limited | 6,419,576 | 1.09% |
| JBWere (NZ) Nominees Limited | 5,269,341 | 0.90% |
| Pt Booster Investments Nominees Limited | 4,991,279 | 0.85% |
| New Zealand Depository Nominee | 4,759,019 | 0.81% |
| FNZ Custodians Limited | 4,083,731 | 0.70% |
